| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.86, 0.99] | | < 1 | | 0% | 8 studies (8/-) | 98.8 % | low | not evaluable | high | crucial | - |
| PFS (extension) | 0.80 [0.69, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 1.04 [0.83, 1.29] | | < 1 | | 90% | 9 studies (9/-) | 37.6 % | low | not evaluable | high | important | - |
| CBR | 1.01 [0.65, 1.55] | | > 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| DCR | 0.49 [0.36, 0.68] | | > 1 | | 25% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| DOR | 0.80 [0.66, 0.97] | | < 1 | | 0% | 3 studies (3/-) | 99.0 % | low | not evaluable | high | non important | - |
| objective responses (ORR) | 1.10 [0.59, 2.07] | | > 1 | | 93% | 8 studies (8/-) | 62.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.47 [1.08, 2.00] | | < 1 | | 0% | 3 studies (3/-) | 0.7 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.24 [0.89, 1.73] | | < 1 | | 69% | 4 studies (4/-) | 10.3 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.97 [0.67, 5.80] | | < 1 | | 0% | 2 studies (2/-) | 10.9 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.83 [1.19, 2.81] | | < 1 | | 43% | 2 studies (2/-) | 0.3 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 1.20 [0.97, 1.48] | | < 1 | | 0% | 3 studies (3/-) | 5.0 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 1.58 [0.84, 2.95] | | < 1 | | 59% | 3 studies (3/-) | 7.7 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.58 [0.99, 2.52] | | < 1 | | 0% | 2 studies (2/-) | 2.8 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.00 [0.55, 1.83] | | < 1 | | 93% | 5 studies (5/-) | 49.6 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.00 [0.45, 2.21] | | < 1 | | 0% | 4 studies (4/-) | 50.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.49 [0.54, 4.14] | | < 1 | | 28% | 2 studies (2/-) | 22.2 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.84 [0.22, 3.26] | | < 1 | | 0% | 2 studies (2/-) | 59.7 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 0.65 [0.17, 2.54] | | < 1 | | 76% | 2 studies (2/-) | 73.3 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.26 [0.28, 5.69] | | < 1 | | 0% | 1 study (1/-) | 38.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.04 [0.10, 10.27] | | < 1 | | 0% | 2 studies (2/-) | 48.7 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.23 [0.05, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.10 [0.50, 2.40] | | < 1 | | 0% | 2 studies (2/-) | 41.0 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.79] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.98 [0.07, 12.73] | | < 1 | | 0% | 2 studies (2/-) | 50.7 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.95 [0.20, 19.31] | | < 1 | | 0% | 2 studies (2/-) | 28.5 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.91 [0.57, 6.42] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.32 [0.70, 2.49] | | < 1 | | 0% | 2 studies (2/-) | 19.5 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.46 [0.07, 3.09] | | < 1 | | 53% | 2 studies (2/-) | 78.8 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 5.72 [0.29, 114.60] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.03 [0.33, 3.14] | | < 1 | | 0% | 2 studies (2/-) | 48.3 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.11 [0.00, 12.49] | | < 1 | | 91% | 2 studies (2/-) | 81.5 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 5.89 [0.74, 47.15] | | < 1 | | 0% | 2 studies (2/-) | 4.8 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 3.82 [0.61, 23.97] | | < 1 | | 0% | 2 studies (2/-) | 7.7 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Urticaria TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.47 [0.04, 5.22] | | < 1 | | 0% | 1 study (1/-) | 72.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.04 [0.48, 2.24] | | < 1 | | 0% | 1 study (1/-) | 46.0 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.72 [0.16, 3.24] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 2.92 [0.59, 14.54] | | < 1 | | 0% | 1 study (1/-) | 9.6 % | NA | not evaluable | | non important | - |
| Cardiomyopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 0.45 [0.07, 2.74] | | < 1 | | 0% | 2 studies (2/-) | 80.7 % | low | not evaluable | high | non important | - |
| Constipation AE (grade 3-4) | 2.91 [0.30, 28.05] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.96 [0.19, 4.80] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.85 [0.33, 2.24] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.96 [0.19, 4.80] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.10 [0.54, 2.22] | | < 1 | | 0% | 1 study (1/-) | 39.9 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.48 [0.09, 2.63] | | < 1 | | 0% | 1 study (1/-) | 80.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.35 [0.11, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 0.96 [0.38, 2.45] | | < 1 | | 0% | 1 study (1/-) | 53.1 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.55 [0.50, 4.79] | | < 1 | | 0% | 1 study (1/-) | 22.2 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.55 [0.50, 4.79] | | < 1 | | 0% | 1 study (1/-) | 22.2 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.94 [0.35, 10.63] | | < 1 | | 0% | 1 study (1/-) | 22.4 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 0.64 [0.11, 3.86] | | < 1 | | 0% | 1 study (1/-) | 68.5 % | NA | not evaluable | | non important | - |
| Myopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.60 [0.19, 1.84] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.02 [0.63, 1.64] | | < 1 | | 0% | 1 study (1/-) | 46.8 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Pericarditis AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 2.07 [1.03, 4.17] | | < 1 | | 0% | 1 study (1/-) | 2.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.16 [0.02, 1.33] | | < 1 | | 0% | 1 study (1/-) | 95.4 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 3.27 [0.89, 11.95] | | < 1 | | 0% | 1 study (1/-) | 3.7 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 3.87 [0.17, 86.09] | | < 1 | | 0% | 1 study (1/-) | 19.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
